Stock Track | Travere Therapeutics Soars 5.86% After-Hours on Strong Q2 Results and FDA Acceptance of Filspari sNDA

Stock Track

2025/08/07

Shares of Travere Therapeutics, Inc. (NASDAQ: TVTX) surged 5.86% in after-hours trading on Wednesday, following the release of the company's impressive second-quarter 2025 financial results and positive regulatory news.

The biopharmaceutical company reported a significant beat on both earnings and revenue for Q2 2025. Travere posted an adjusted earnings per share of $0.13, surpassing the analyst consensus estimate of -$0.28 by 146.43%. This marks a substantial improvement from the loss of $0.65 per share in the same period last year. Revenue for the quarter came in at $114.4 million, beating the analyst expectations of $101.38 million by 12.85% and representing a remarkable 119.26% increase year-over-year.

Adding to the positive sentiment, Travere announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) for Filspari in the treatment of focal segmental glomerulosclerosis (FSGS). The PDUFA date has been set for January 13, 2026, potentially expanding the drug's market reach. Furthermore, the company reported a 165% surge in FILSPARI sales, contributing significantly to the strong quarterly performance. These developments have bolstered investor confidence in Travere's growth prospects and pipeline progress, likely driving the after-hours stock price increase.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎國際,美股交易,港股交易,交易美股,股票信息,股價,美股行情,美股打新,港股打新,IPO打新,購買美股,全球投資","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1119661003"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1119661003\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1119661003?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-07 06:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1119661003","market":"sg","top_or_hot":-1,"title":"Stock Track | Travere Therapeutics Soars 5.86% After-Hours on Strong Q2 Results and FDA Acceptance of Filspari sNDA","media":"Stock Track","content":"<p>Shares of Travere Therapeutics, Inc. (NASDAQ: TVTX) surged 5.86% in after-hours trading on Wednesday, following the release of the company's impressive second-quarter 2025 financial results and positive regulatory news.</p>\n\n<p>The biopharmaceutical company reported a significant beat on both earnings and revenue for Q2 2025. Travere posted an adjusted earnings per share of $0.13, surpassing the analyst consensus estimate of -$0.28 by 146.43%. This marks a substantial improvement from the loss of $0.65 per share in the same period last year. Revenue for the quarter came in at $114.4 million, beating the analyst expectations of $101.38 million by 12.85% and representing a remarkable 119.26% increase year-over-year.</p>\n\n<p>Adding to the positive sentiment, Travere announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) for Filspari in the treatment of focal segmental glomerulosclerosis (FSGS). The PDUFA date has been set for January 13, 2026, potentially expanding the drug's market reach. Furthermore, the company reported a 165% surge in FILSPARI sales, contributing significantly to the strong quarterly performance. These developments have bolstered investor confidence in Travere's growth prospects and pipeline progress, likely driving the after-hours stock price increase.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Travere Therapeutics Soars 5.86% After-Hours on Strong Q2 Results and FDA Acceptance of Filspari sNDA</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Travere Therapeutics Soars 5.86% After-Hours on Strong Q2 Results and FDA Acceptance of Filspari sNDA\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2025-08-07 06:12</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Shares of Travere Therapeutics, Inc. (NASDAQ: TVTX) surged 5.86% in after-hours trading on Wednesday, following the release of the company's impressive second-quarter 2025 financial results and positive regulatory news.</p>\n\n<p>The biopharmaceutical company reported a significant beat on both earnings and revenue for Q2 2025. Travere posted an adjusted earnings per share of $0.13, surpassing the analyst consensus estimate of -$0.28 by 146.43%. This marks a substantial improvement from the loss of $0.65 per share in the same period last year. Revenue for the quarter came in at $114.4 million, beating the analyst expectations of $101.38 million by 12.85% and representing a remarkable 119.26% increase year-over-year.</p>\n\n<p>Adding to the positive sentiment, Travere announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) for Filspari in the treatment of focal segmental glomerulosclerosis (FSGS). The PDUFA date has been set for January 13, 2026, potentially expanding the drug's market reach. Furthermore, the company reported a 165% surge in FILSPARI sales, contributing significantly to the strong quarterly performance. These developments have bolstered investor confidence in Travere's growth prospects and pipeline progress, likely driving the after-hours stock price increase.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TVTX","symbol_name":"Travere Therapeutics, Inc.","start_time":0,"source_url":"","article_id":"1119661003","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1119661003","pubTimestamp":1754518353,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Travere Therapeutics, Inc. (NASDAQ: TVTX) surged 5.86% in after-hours trading on Wednesday, following the release of the company's impressive second-quarter 2025 financial results and...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TVTX":"Travere Therapeutics, Inc."},"translate_title":"个股追踪|Travere Therapeutics盘后大涨5.86%Q2业绩强劲且FDA接受Filspari sNDA","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TVTX":1},"content_text":"Shares of Travere Therapeutics, Inc. (NASDAQ: TVTX) surged 5.86% in after-hours trading on Wednesday, following the release of the company's impressive second-quarter 2025 financial results and positive regulatory news.\nThe biopharmaceutical company reported a significant beat on both earnings and revenue for Q2 2025. Travere posted an adjusted earnings per share of $0.13, surpassing the analyst consensus estimate of -$0.28 by 146.43%. This marks a substantial improvement from the loss of $0.65 per share in the same period last year. Revenue for the quarter came in at $114.4 million, beating the analyst expectations of $101.38 million by 12.85% and representing a remarkable 119.26% increase year-over-year.\nAdding to the positive sentiment, Travere announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) for Filspari in the treatment of focal segmental glomerulosclerosis (FSGS). The PDUFA date has been set for January 13, 2026, potentially expanding the drug's market reach. Furthermore, the company reported a 165% surge in FILSPARI sales, contributing significantly to the strong quarterly performance. These developments have bolstered investor confidence in Travere's growth prospects and pipeline progress, likely driving the after-hours stock price increase.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}